Pharmaceuticals

Rising Chronic Conditions Is A Catalyst For Growth In The Extended-Release Drug Market Is Supporting Development Across The Extended-Release Drugs Market

May 19, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Extended-Release Drugs Market Compare Between 2026 And 2030?

The extended-release drugs market size has seen rapid expansion over recent years. Forecasts indicate an increase from $69.63 billion in 2025 to $77.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.9%. The market’s historical growth can be linked to factors such as the rising prevalence of chronic diseases, a growing demand for patient-centric drug formulations, the limitations inherent in immediate-release drugs, increasing healthcare expenditure, and advancements in pharmaceutical excipients.

The extended-release drugs market size is projected to experience substantial growth in the coming years. It is anticipated to reach **$126.89 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%.** This growth during the forecast period is attributable to the expansion of precision medicine, increasing adoption of oral controlled-release formulations, the proliferation of hospital and retail pharmacies, a rising geriatric population, and investments in novel delivery technologies. Prominent trends expected in this period include personalized dosage regimens, advanced drug delivery systems, optimization of patient adherence, innovative formulation technologies, and extended-release combination therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp

Which Strategic Drivers Are Supporting The Extended-Release Drugs Market Development?

The rising prevalence of chronic health issues is projected to fuel the expansion of the extended-release drug market in the future. These long-term ailments are defined as conditions that persist for a year or longer, necessitating continuous medical care, restricting daily activities, or both. Heart disease, cancer, obesity, and diabetes are prominent examples. Extended-release drug delivery systems are engineered to maintain a relatively constant level of medication in the body over a prolonged period. This design helps sustain a consistent therapeutic effect and prevents the fluctuations in drug levels that can occur with immediate-release medications. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Consequently, the increasing incidence of chronic conditions is a key driver for the growth of the extended-release drug market.

How Does Segment Analysis Break Down The Extended-Release Drugs Market Structure?

The extended-release drugs market covered in this report is segmented –

1) By Type: Sustained Release Drug, Controlled Release Drug

2) By Mode: Over-The-Counter, Prescription

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:

1) By Sustained Release Drug: Matrix Systems, Coating Systems

2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

What Trends Are Influencing The Extended-Release Drugs Market?

Major companies operating in the extended-release drugs market are developing innovative products like next-generation extended-release tablets to enhance their product offerings and secure a competitive advantage. Extended-release tablets are a type of pharmaceutical formulation designed to gradually release their active ingredients over an extended period. For instance, in February 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for austedo XR (deutetrabenazine). Austedo XR is recommended for the treatment of adults with chorea and tardive dyskinesia related to Huntington disease, available in dosages of 6, 12, and 24 mg. With the approval of austedo XR, patients experiencing tardive dyskinesia and Huntington disease chorea now have another efficient treatment option, enabling individuals to manage these disorders with medication administered once daily. The development of austedo XR, which offers a practical and efficient therapeutic alternative for those with certain movement disorders, signifies a considerable advancement in the management of these ailments.

Which Companies Are Engaged In The Extended-Release Drugs Market Environment?

Major companies operating in the extended-release drugs market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Watson Pharmaceuticals Inc.

Access The Complete Extended-Release Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

Which Region Holds The Largest Share In The Extended-Release Drugs Market?

North America was the largest region in the extended-release drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Extended-Release Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp

Browse Through More Reports Similar to the Global Extended-Release Drugs Market 2026, By The Business Research Company

Extended Release Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

Controlled Release Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/controlled-release-drug-delivery-global-market-report

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795